Postdoctoral fellows and professor of medicine

Main research interests：Osteoporosis, osteopenia and bone biology.

Prof. Yao was the deputy director and professor of Musculoskeletal Health Research Center of UC Davis School of Medicine. As the project leader, she has undertaken scientific research projects such as National Institutes of Health (NIH), California Institute of Regenerative Medicine (CIRM), American Natural Science Foundation project "Study on Bone-Targeted Guided Mesenchymal Stem Cell Migration for Osteogenesis", "Research Project of Mesenchymal Stem Cells for Osteoporosis, Fracture Healing and Rheumatoid Arthropathy" and "Interference with Progesterone Receptor for Osteoporosis", and obtained more than 20 million US dollars of large-scale special research funds from NIH and CIRM.
         

Prof. Yao won substantial awards, including "UCD avis Award for Outstanding Scientific Research in 2012" and "UC Davis Medical College Award for Outstanding Scientific Research Team in 2013", "Benefit Human Health Award" and "Best Tutor Award" in 2016. She has published more than 100 SCI papers in internationally renowned journals such as Nature Medicine, Stem Cells and Nature Communications; She is currently the chairman of the Bone and Joint Branch of the Orthopedic research society.

Prof. Yao has also participated in the R&D of new drugs for many renowned companies such as Eli Lilly, Merck, Glaxo Smith Kline (GSK), P&G and Amgen, and  has extensive experience in the industrialization of innovative drugs.

 As the co-founder and CSO  of Rabpharma, Prof. Yao is now leading the phase II clinical trial of Innovative Drug Program Rab001 for the treatment of osteonecrosis in China.

Founded in 2021, Laibo Ruichen is committed to the independent research and development and industrialization promotion of "First-in-Class" innovative drugs for bone and joint, and provides innovative treatment programs for the majority of bone and joint patients based on the unmet clinical drug demand in China and the world.

The original project team is from UC Davis Bone and Joint Regenerative Medicine Research Center; R&D has been carried out for more than 12 years, and the accumulated investment exceeds 30 million US dollars; Global originality, leading technology and high barriers can fill the gap in the market; The intellectual property rights are clear and authorized, and the research and development achievements have been published in many top scientific magazines in the world.

Mr Chen has over 20 years of  entrepreneurial and senior management experience in US Silicon Valley biotech startups.  And he successfully founded software outsourcing and international trading companies, serving as a global supplier and business advisor to major retailers like Costco, Walmart, and HSN. 

He excels in corporate structure establishment, business management, product development, market expansion, and patent protection, among other areas. He once founded and served as General Manager of Rabome, a U.S.-based pharmaceutical company specializing in bone and joint regeneration. During his tenure, he completed the signing and rights transfer of multiple PCT patent agreements and helped the company secure $23 million in government funding.

Founded in 2005, Nuovo Technology is a mature integrated Internet application service provider and a national certified dual soft and high-tech enterprise.